Co-amorphous systems for the delivery of poorly water-soluble drugs: recent advances and an update

References

• Di L, Fish PV, Mano T. Bridging solubility between drug discovery and development. Drug Discov Today. 2012;17(9–10):486–495.
   PubMed Web of Science ®Google Scholar
• Shi Q, Moinuddin SM, Cai T. Advances in coamorphous drug delivery systems. Acta pharm Sin B. 2019;9(1):19–35.
   PubMed Web of Science ®Google Scholar
• Qian S, Heng W, Wei Y, et al. Coamorphous lurasidone hydrochloride–saccharin with charge-assisted hydrogen bonding interaction shows improved physical stability and enhanced dissolution with pH-independent solubility behavior. Cryst Growth Des. 2015;15(6):2920–2928.
   Web of Science ®Google Scholar
• Hsu CM, Yu SC, Tsai FJ, et al. Characterization of in vitro and in vivo bioactivity of a ferulic acid-2-Hydroxypropyl-beta-cyclodextrin inclusion complex. Colloids Surf B: Biointerfaces. 2019;180:68–74.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Corvis Y, Gahoual R, et al. Conception of nanosized hybrid liposome/poloxamer particles to thicken the interior core of liposomes and delay hydrophilic drug delivery. Int J Pharm. 2019;567:118488.
   PubMed Web of Science ®Google Scholar
• Vasconcelos T, Marques S, Das Neves J, et al. Amorphous solid dispersions: rational selection of a manufacturing process. Adv Drug Deliv Rev. 2016;100:85–101.
   PubMed Web of Science ®Google Scholar
• Abdulkarim M, Sharma PK, Gumbleton M. Self-emulsifying drug delivery system: mucus permeation and innovative quantification technologies. Adv Drug Deliv Rev. 2019;142:62–74.
   PubMed Web of Science ®Google Scholar
• Hou G, Wang Z, Ma H, et al. High-temperature stable plasmonic and cavity resonances in metal nanoparticle-decorated silicon nanopillars for strong broadband absorption in photothermal applications. Nanoscale. 2019;11:14777–14784.
   PubMed Web of Science ®Google Scholar
• Trubitsyn G, Nga Nguyen V, Di Tommaso C, et al. Impact of covalently nile red and covalently rhodamine labeled fluorescent polymer micelles for the improved imaging of the respective drug delivery system. Eur J Pharm Biopharm. 2019;142:480–487.
   PubMed Web of Science ®Google Scholar
• Sverdlov Arzi R, Sosnik A. Electrohydrodynamic atomization and spray-drying for the production of pure drug nanocrystals and co-crystals. Adv Drug Deliv Rev. 2018;131:79–100.
   PubMed Web of Science ®Google Scholar
• Wang R, Han J, Jiang A, et al. Involvement of metabolism-permeability in enhancing the oral bioavailability of curcumin in excipient-free solid dispersions co-formed with piperine. Int J Pharm. 2019;561:9–18.
   PubMed Web of Science ®Google Scholar
• Kasten G, Lobmann K, Grohganz H, et al. Co-former selection for co-amorphous drug-amino acid formulations. Int J Pharm. 2019;557:366–373.
   PubMedGoogle Scholar
• Shi X, Song S, Ding Z, et al. Improving the solubility, dissolution, and bioavailability of ibrutinib by preparing it in a coamorphous state with saccharin. J Pharm Sci. 2019;108:3020–3028.
   PubMed Web of Science ®Google Scholar
• Wu W, Lobmann K, Rades T, et al. On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems. Int J Pharm. 2018;535(1–2):86–94.
   PubMed Web of Science ®Google Scholar
• Fung MH, DeVault M, Kuwata KT, et al. Drug-excipient interactions: effect on molecular mobility and physical stability of ketoconazole-organic acid coamorphous systems. Mol Pharm. 2018;15(3):1052–1061.
   PubMedGoogle Scholar
• Chavan RB, Thipparaboina R, Kumar D, et al., Co amorphous systems: a product development perspective. Int J Pharm. 2016;515(1–2): 403–415.
   PubMed Web of Science ®Google Scholar
• Lu W, Rades T, Rantanen J, et al. Inhalable co-amorphous budesonide-arginine dry powders prepared by spray drying. Int J Pharm. 2019;565:1–8.
   PubMedGoogle Scholar
• Moinuddin SM, Ruan S, Huang Y, et al. Facile formation of co-amorphous atenolol and hydrochlorothiazide mixtures via cryogenic-milling: enhanced physical stability, dissolution and pharmacokinetic profile. Int J Pharm. 2017;532(1):393–400.
   PubMedGoogle Scholar
• Li B, Konecke S, Wegiel LA, et al. Both solubility and chemical stability of curcumin are enhanced by solid dispersion in cellulose derivative matrices. Carbohyd Polym. 2013;98(1):1108–1116.
   PubMed Web of Science ®Google Scholar
• Korhonen O, Pajula K, Laitinen R. Rational excipient selection for co-amorphous formulations. Expert Opin Drug Deliv. 2017;14(4):551–569.
   PubMed Web of Science ®Google Scholar
• Knapik-Kowalczuk J, Chmiel K, Jurkiewicz K, et al. Physical stability and viscoelastic properties of co-amorphous ezetimibe/simvastatin system. Pharmaceuticals. 2019;12(1):40.
   Web of Science ®Google Scholar
• Bohr A, Nascimento TL, Harmankaya N, et al. Efflux inhibitor bicalutamide increases oral bioavailability of the poorly soluble efflux substrate docetaxel in co-amorphous anti-cancer combination therapy. Molecules. 2019;24(2):266.
   Web of Science ®Google Scholar
• Russo MG, Baldoni HA, Davila YA, et al. Rational design of a famotidine-ibuprofen coamorphous system: an experimental and theoretical study. J Phys Chem B. 2018;122(37):8772–8782.
   PubMed Web of Science ®Google Scholar
• Meng-Lund H, Kasten G, Jensen KT, et al. The use of molecular descriptors in the development of co-amorphous formulations. Eur J Pharm Sci. 2018;119:31–38.
   PubMed Web of Science ®Google Scholar
• Tilborg A, Norberg B, Wouters J. Pharmaceutical salts and cocrystals involving amino acids: A brief structural overview of the state-of-art. Eur J Med Chem. 2014;74:411–426.
   PubMed Web of Science ®Google Scholar
• Kasten G, Lobo L, Dengale S, et al. In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine. Eur J Pharm Biopharm. 2018;132:192–199.
   PubMed Web of Science ®Google Scholar
• Ojarinta R, Saarinen J, Strachan CJ, et al. Preparation and characterization of multi-component tablets containing co-amorphous salts: combining multimodal non-linear optical imaging with established analytical methods. Eur J Pharm Biopharm. 2018;132:112–126.
   PubMed Web of Science ®Google Scholar
• Mishra J, Rades T, Lobmann K, et al. Influence of solvent composition on the performance of spray-dried co-amorphous formulations. Pharmaceutics. 2018;10(2):47.
   Web of Science ®Google Scholar
• Kasten G, Nouri K, Grohganz H, et al. Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine. Int J Pharm. 2017;533(1):138–144.
   PubMedGoogle Scholar
• Ojarinta R, Lerminiaux L, Laitinen R. Spray drying of poorly soluble drugs from aqueous arginine solution. Int J Pharm. 2017;532(1):289–298.
   PubMedGoogle Scholar
• Kasten G, Grohganz H, Rades T, et al. Development of a screening method for co-amorphous formulations of drugs and amino acids. Eur J Pharm Sci. 2016;95:28–35.
   PubMed Web of Science ®Google Scholar
• Wu W, Ueda H, Lobmann K, et al. Organic acids as co-formers for co-amorphous systems - influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems. Eur J Pharm Biopharm. 2018;131:25–32.
   PubMed Web of Science ®Google Scholar
• Wu W, Wang Y, Lobmann K, et al. Transformations between co-amorphous and co-crystal systems and their influence on the formation and physical stability of co-amorphous systems. Mol Pharm. 2019;16(3):1294–1304.
   PubMedGoogle Scholar
• An JH, Lim C, Kiyonga AN, et al. Co-amorphous screening for the solubility enhancement of poorly water-soluble mirabegron and investigation of their intermolecular interactions and dissolution behaviors. Pharmaceutics. 2018;10(3):149.
   PubMed Web of Science ®Google Scholar
• Gniado K, MacFhionnghaile P, McArdle P, et al. The natural bile acid surfactant sodium taurocholate (NaTC) as a coformer in coamorphous systems: enhanced physical stability and dissolution behavior of coamorphous drug-NaTc systems. Int J Pharm. 2018;535(1–2):132–139.
   PubMedGoogle Scholar
• Fung M, Be Rzins KR, Suryanarayanan R. Physical stability and dissolution behavior of ketoconazole-organic acid coamorphous systems. Mol Pharm. 2018;15(5):1862–1869.
   PubMedGoogle Scholar
• Lobmann K, Laitinen R, Strachan C, et al. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs–Part 2: molecular interactions. Eur J Pharm Biopharm. 2013;85:882–888.
   PubMed Web of Science ®Google Scholar
• Kissi EO, Kasten G, Lobmann K, et al. The role of glass transition temperatures in coamorphous drug-amino acid formulations. Mol Pharm. 2018;15(9):4247–4256.
   PubMedGoogle Scholar
• Petry I, Lobmann K, Grohganz H, et al. In situ co-amorphisation in coated tablets - The combination of carvedilol with aspartic acid during immersion in an acidic medium. Int J Pharm. 2019;558:357–366.
   PubMedGoogle Scholar
• Laitinen R, Lobmann K, Grohganz H, et al. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability. Mol Pharm. 2014;11(7):2381–2389.
   PubMed Web of Science ®Google Scholar
• Ruponen M, Visti M, Ojarinta R, et al. Permeability of glibenclamide through a PAMPA membrane: the effect of co-amorphization. Eur J Pharm Biopharm. 2018;129:247–256.
   PubMed Web of Science ®Google Scholar
• Franca MT, Marcos TM, Pereira RN, et al. Could the small molecules such as amino acids improve aqueous solubility and stabilize amorphous systems containing Griseofulvin? Eur J Pharm Sci. 2019;143:105178.
   PubMed Web of Science ®Google Scholar
• Petry I, Lobmann K, Grohganz H, et al. Undesired co-amorphisation of indomethacin and arginine during combined storage at high humidity conditions. Int J Pharm. 2018;544(1):172–180.
   PubMedGoogle Scholar
• Wu W, Lobmann K, Schnitzkewitz J, et al. Dipeptides as co-formers in co-amorphous systems. Eur J Pharm Biopharm. 2019;134:68–76.
   PubMed Web of Science ®Google Scholar
• Craye G, Lobmann K, Grohganz H, et al. Characterization of amorphous and co-amorphous simvastatin formulations prepared by spray drying. Molecules. 2015;20(12):21532–21548.
   PubMed Web of Science ®Google Scholar
• Lu W, Rades T, Rantanen J, et al. Amino acids as stabilizers for spray-dried simvastatin powder for inhalation. Int J Pharm. 2019;572:118724.
   PubMedGoogle Scholar
• Huang Y, Zhang Q, Wang JR, et al. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan. Pharm Dev Technol. 2017;22(1):69–76.
   PubMed Web of Science ®Google Scholar
• Pan Y, Pang W, Lv J, et al. Solid state characterization of azelnidipine-oxalic acid co-crystal and co-amorphous complexes: the effect of different azelnidipine polymorphs. J Pharm Biomed Anal. 2017;138:302–315.
   PubMed Web of Science ®Google Scholar
• Ali AM, Ali AA, Maghrabi IA. Clozapine-carboxylic acid plasticized co-amorphous dispersions: preparation, characterization and solution stability evaluation. Acta Pharm. 2015;65(2):133–146.
   PubMed Web of Science ®Google Scholar
• Al-Hamidi H, Edwards AA, Mohammad MA, et al. To enhance dissolution rate of poorly water-soluble drugs: glucosamine hydrochloride as a potential carrier in solid dispersion formulations. Colloids Surf B: Biointerfaces. 2010;76(1):170–178.
   PubMed Web of Science ®Google Scholar
• Madgulkar A, Bandivadekar M, Shid T, et al. Sugars as solid dispersion carrier to improve solubility and dissolution of the BCS class II drug: clotrimazole. Drug Dev Ind Pharm. 2016;42(1):28–38.
   PubMed Web of Science ®Google Scholar
• Takeda K, Sekitoh T, Fujioka A, et al. Physical stability of an amorphous sugar matrix dried from methanol as an amorphous solid dispersion carrier and the influence of heat treatment. J Pharm Sci. 2019;108(6):2056–2062.
   PubMed Web of Science ®Google Scholar
• Kaminska E, Adrjanowicz K, Tarnacka M, et al. Impact of inter- and intramolecular interactions on the physical stability of indomethacin dispersed in acetylated saccharides. Mol Pharm. 2014;11(8):2935–2947.
   PubMedGoogle Scholar
• Kaminska E, Adrjanowicz K, Zakowiecki D, et al. Enhancement of the physical stability of amorphous indomethacin by mixing it with octaacetylmaltose. inter and intra molecular studies. Pharm Res. 2014;31(10):2887–2903.
   PubMed Web of Science ®Google Scholar
• Kaminska E, Madejczyk O, Tarnacka M, et al. Studying of crystal growth and overall crystallization of naproxen from binary mixtures. Eur J Pharm Biopharm. 2017;113:75–87.
   PubMed Web of Science ®Google Scholar
• Zajc N, Obreza A, Bele M, et al. Physical properties and dissolution behaviour of nifedipine/mannitol solid dispersions prepared by hot melt method. Int J Pharm. 2005;291(1–2):51–58.
   PubMedGoogle Scholar
• Kaminska E, Tarnacka M, Wlodarczyk P, et al. Studying the impact of modified saccharides on the molecular dynamics and crystallization tendencies of model API nifedipine. Mol Pharm. 2015;12(8):3007–3019.
   PubMedGoogle Scholar
• Shayanfar A, Ghavimi H, Hamishehkar H, et al. Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties. J Pharm Pharm Sci. 2013;16(4):577–587.
   PubMed Web of Science ®Google Scholar
• Khan MZ, Rausl D, Zanoski R, et al. Classification of loratadine based on the biopharmaceutics drug classification concept and possible in vitro-in vivo correlation. Biol Pharm Bull. 2004;27(10):1630–1635.
   PubMed Web of Science ®Google Scholar
• Sora DI, Udrescu S, David V, et al. Validated ion pair liquid chromatography/fluorescence detection method for assessing the variability of the loratadine metabolism occurring in bioequivalence studies. Biomed Chromatogr. 2007;21(10):1023–1029.
   PubMed Web of Science ®Google Scholar
• Wang J, Chang R, Zhao Y, et al. Coamorphous loratadine-citric acid system with enhanced physical stability and bioavailability. AAPS PharmSciTech. 2017;18(7):2541–2550.
   PubMed Web of Science ®Google Scholar
• Ainurofiq A, Mauludin R, Mudhakir D, et al. A novel desloratadine-benzoic acid co-amorphous solid: preparation, characterization, and stability evaluation. Pharmaceutics. 2018;10(3):85.
   Web of Science ®Google Scholar
• Martinez LM, Videa M, Lopez Silva T, et al. Two-phase amorphous-amorphous solid drug dispersion with enhanced stability, solubility and bioavailability resulting from ultrasonic dispersion of an immiscible system. Eur J Pharm Biopharm. 2017;119:243–252.
   PubMed Web of Science ®Google Scholar
• Takeda K, Gotoda Y, Hirota D, et al. Surfactant-free solid dispersions of hydrophobic drugs in an amorphous sugar matrix dried from an organic solvent. Mol Pharm. 2017;14(3):791–798.
   PubMed Web of Science ®Google Scholar
• Satoh T, Hidaka F, Miyake K, et al. Surfactant-free solid dispersion of fat-soluble flavour in an amorphous sugar matrix. Food Chem. 2016;197:1136–1142.
   PubMed Web of Science ®Google Scholar
• Das A, Nayak AK, Mohanty B, et al. Solubility and dissolution enhancement of etoricoxib by solid dispersion technique using sugar carriers. ISRN Pharm. 2011;2011:819765.
   PubMedGoogle Scholar
• Huang R, Han J, Wang R, et al. Surfactant-free solid dispersion of BCS class IV drug in an amorphous chitosan oligosaccharide matrix for concomitant dissolution in vitro - permeability increase. Eur J Pharm Sci. 2019;130:147–155.
   PubMed Web of Science ®Google Scholar
• Kulthe VV, Chaudhari PD, Aboul-Enein HY. Freeze-dried amorphous dispersions for solubility enhancement of thermosensitive API having low molecular lipophilicity. Drug Res. 2014;64(9):493–498.
   Google Scholar
• Kaminska E, Tarnacka M, Kolodziejczyk K, et al. Impact of low molecular weight excipient octaacetylmaltose on the liquid crystalline ordering and molecular dynamics in the supercooled liquid and glassy state of itraconazole. Eur J Pharm Biopharm. 2014;88(3):1094–1104.
   PubMed Web of Science ®Google Scholar
• Bi Y, Xiao D, Ren S, et al. The binary system of ibuprofen-nicotinamide under nanoscale confinement: from cocrystal to coamorphous state. J Pharm Sci. 2017;106(10):3150–3155.
   PubMed Web of Science ®Google Scholar
• Gniado K, Lobmann K, Rades T, et al. The influence of co-formers on the dissolution rates of co-amorphous sulfamerazine/excipient systems. Int J Pharm. 2016;504(1–2):20–26.
   PubMedGoogle Scholar
• Wu W, Lobmann K, Schnitzkewitz J, et al. Aspartame as a co-former in co-amorphous systems. Int J Pharm. 2018;549(1–2):380–387.
   PubMedGoogle Scholar
• Gao Y, Liao J, Qi X, et al. Coamorphous repaglinide-saccharin with enhanced dissolution. Int J Pharm. 2013;450(1–2):290–295.
   PubMed Web of Science ®Google Scholar
• Ueda H, Kadota K, Imono M, et al. Co-amorphous formation induced by combination of tranilast and diphenhydramine hydrochloride. J Pharm Sci. 2017;106(1):123–128.
   PubMed Web of Science ®Google Scholar
• Dengale SJ, Grohganz H, Rades T, et al. Recent advances in co-amorphous drug formulations. Adv Drug Deliv Rev. 2016;100:116–125.
   PubMed Web of Science ®Google Scholar
• Haneef J, Chadha R. Drug-drug multicomponent solid forms: cocrystal, coamorphous and eutectic of three poorly soluble antihypertensive drugs using mechanochemical approach. AAPS PharmSciTech. 2017;18(6):2279–2290.
   PubMed Web of Science ®Google Scholar
• Hirakawa Y, Ueda H, Wakabayashi R, et al. A novel binary supercooled liquid formulation for transdermal drug delivery. Biol Pharm Bull. 2020;43(3):393–398.
   PubMed Web of Science ®Google Scholar
• Wairkar S, Gaud R. Co-amorphous combination of nateglinide-metformin hydrochloride for dissolution enhancement. AAPS PharmSciTech. 2016;17(3):673–681.
   PubMed Web of Science ®Google Scholar
• Lodagekar A, Chavan RB, Mannava MKC, et al. Co amorphous valsartan nifedipine system: preparation, characterization, in vitro and in vivo evaluation. Eur J Pharm Sci. 2019;139:105048.
   PubMed Web of Science ®Google Scholar
• Mannava MKC, Suresh K, Kumar Bommaka M, et al. Curcumin-artemisinin coamorphous solid: xenograft model preclinical study. Pharmaceutics. 2018;10(1):7.
   Web of Science ®Google Scholar
• Lababidi N, Ofosu Kissi E, Elgaher WAM, et al. Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis. J Control Release. 2019;314:62–71.
   PubMed Web of Science ®Google Scholar
• Dengale SJ, Hussen SS, Krishna BSM, et al. Fabrication, solid state characterization and bioavailability assessment of stable binary amorphous phases of ritonavir with quercetin. Eur J Pharm Biopharm. 2015;89:329–338.
   PubMed Web of Science ®Google Scholar
• Sanphui P, Devi VK, Clara D, et al. Cocrystals of hydrochlorothiazide: solubility and diffusion/permeability enhancements through drug-coformer interactions. Mol Pharm. 2015;12(5):1615–1622.
   PubMed Web of Science ®Google Scholar
• Lobmann K, Laitinen R, Grohganz H, et al. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen. Mol Pharm. 2011;8(5):1919–1928.
   PubMed Web of Science ®Google Scholar
• Li H, Pan T, Cui Y, et al. Improved oral bioavailability of poorly water-soluble glimepiride by utilizing microemulsion technique. Int J Nanomedicine. 2016;11:3777–3788.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu W, Lin Q, et al. Hydroxypropyl-beta-cyclodextrin functionalized calcium carbonate microparticles as a potential carrier for enhancing oral delivery of water-insoluble drugs. Int J Nanomedicine. 2015;10:3291–3302.
   PubMed Web of Science ®Google Scholar
• Cruz-Angeles J, Videa M, Martinez LM. Highly soluble glimepiride and irbesartan co-amorphous formulation with potential application in combination therapy. AAPS PharmSciTech. 2019;20(4):144.
   PubMed Web of Science ®Google Scholar
• Lobmann K, Strachan C, Grohganz H, et al. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. Eur J Pharm Biopharm. 2012;81(1):159–169.
   PubMed Web of Science ®Google Scholar
• Leng D, Kissi EO, Lobmann K, et al. Design of inhalable solid dosage forms of budesonide and theophylline for pulmonary combination therapy. AAPS PharmSciTech. 2019;20(3):137.
   PubMed Web of Science ®Google Scholar
• Arnfast L, Kamruzzaman M, Lobmann K, et al. Melt extrusion of high-dose co-amorphous drug-drug combinations. Pharma Res. 2017;34(12):2689–2697.
   Google Scholar
• Martinez-Jimenez C, Cruz-Angeles J, Videa M, et al. Co-amorphous simvastatin-nifedipine with enhanced solubility for possible use in combination therapy of hypertension and hypercholesterolemia. Molecules. 2018;23(9):2161.
   Web of Science ®Google Scholar
• Newman A, Reutzel-Edens SM, Zografi G. Coamorphous active pharmaceutical ingredient-small molecule mixtures: considerations in the choice of coformers for enhancing dissolution and oral bioavailability. J Pharm Sci. 2018;107(1):5–17.
   PubMed Web of Science ®Google Scholar
• Lobmann K, Grohganz H, Laitinen R, et al. Amino acids as co-amorphous stabilizers for poorly water soluble drugs–Part 1: preparation, stability and dissolution enhancement. Eur J Pharm Biopharm. 2013;85:873–881.
   PubMed Web of Science ®Google Scholar
• Mohammad MA, Alhalaweh A, Velaga SP. Hansen solubility parameter as a tool to predict cocrystal formation. Int J Pharm. 2011;407(1–2):63–71.
   PubMedGoogle Scholar
• Salem A, Nagy S, Pal S, et al. Reliability of the Hansen solubility parameters as co-crystal formation prediction tool. Int J Pharm. 2019;558:319–327.
   PubMedGoogle Scholar
• Metre S, Mukesh S, Samal SK, et al., Enhanced biopharmaceutical performance of rivaroxaban through polymeric amorphous solid dispersion. Mol Pharm. 2018;15(2): 652–668.
   PubMed Web of Science ®Google Scholar
• Pajula K, Wittoek L, Lehto VP, et al. Phase separation in coamorphous systems: in silico prediction and the experimental challenge of detection. Mol Pharm. 2014;11(7):2271–2279.
   PubMedGoogle Scholar
• Baird JA, Taylor LS. Evaluation of amorphous solid dispersion properties using thermal analysis techniques. Adv Drug Deliv Rev. 2012;64(5):396–421.
   PubMed Web of Science ®Google Scholar
• Lopez FL, Shearman GC, Gaisford S, et al. Amorphous formulations of indomethacin and griseofulvin prepared by electrospinning. Mol Pharm. 2014;11(12):4327–4338.
   PubMedGoogle Scholar
• Safna Hussan KP, Thayyil MS, Deshpande SK, et al. Molecular dynamics, physical and thermal stability of neat amorphous amlodipine besylate and in binary mixture. Eur J Pharm Sci. 2018;119:268–278.
   PubMed Web of Science ®Google Scholar
• Cordeiro T, Castineira C, Mendes D, et al. Stabilizing unstable amorphous menthol through inclusion in mesoporous silica hosts. Mol Pharm. 2017;14(9):3164–3177.
   PubMedGoogle Scholar
• Zhu S, Gao H, Babu S, et al. Co-amorphous formation of high-dose zwitterionic compounds with amino acids to improve solubility and enable parenteral delivery. Mol Pharm. 2018;15(1):97–107.
   PubMedGoogle Scholar
• Russo MG, Sancho MI, Silva LMA, et al. Looking for the interactions between omeprazole and amoxicillin in a disordered phase. An experimental and theoretical study. Spectrochim Acta A. 2016;156:70–77.
   PubMed Web of Science ®Google Scholar
• Sormunen H, Ruponen M, Laitinen R. The effect of co-amorphization of glibenclamide on its dissolution properties and permeability through an MDCKII-MDR1 cell layer. Int J Pharm. 2019;570:118653.
   PubMedGoogle Scholar
• Murtaza G. Solubility enhancement of simvastatin: A review. Acta Pol Pharm. 2012;69(4):581–590.
   PubMed Web of Science ®Google Scholar
• Keratichewanun S, Yoshihashi Y, Sutanthavibul N, et al. An investigation of nifedipine miscibility in solid dispersions using raman spectroscopy. Pharm Res. 2015;32(7):2458–2473.
   PubMed Web of Science ®Google Scholar
• Bates S, Zografi G, Engers D, et al. Analysis of amorphous and nanocrystalline solids from their X-ray diffraction patterns. Pharm Res. 2006;23(10):2333–2349.
   PubMed Web of Science ®Google Scholar
• Healy AM, Worku ZA, Kumar D, et al. Pharmaceutical solvates, hydrates and amorphous forms: a special emphasis on cocrystals. Adv Drug Deliv Rev. 2017;117:25–46.
   PubMed Web of Science ®Google Scholar
• Maher EM, Ali AM, Salem HF, et al. In vitro/in vivo evaluation of an optimized fast dissolving oral film containing olanzapine co-amorphous dispersion with selected carboxylic acids. Drug Deliv. 2016;23(8):3088–3100.
   PubMed Web of Science ®Google Scholar
• Karagianni A, Kachrimanis K, Nikolakakis I. Co-amorphous solid dispersions for solubility and absorption improvement of drugs: composition, preparation, characterization and formulations for oral delivery. Pharmaceutics. 2018;10(3):98.
   PubMed Web of Science ®Google Scholar
• Singh A. Van den Mooter G. Spray drying formulation of amorphous solid dispersions. Adv Drug Deliv Rev. 2016;100:27–50.
   PubMed Web of Science ®Google Scholar
• Sai Krishna Anand V, Sakhare SD, Navya SKS, et al. The relevance of co-amorphous formulations to develop supersaturated dosage forms: in-vitro, and ex-vivo investigation of ritonavir-lopinavir co-amorphous materials. Eur J Pharm Sci. 2018;123:124–134.
   PubMed Web of Science ®Google Scholar
• Lenz E, Jensen KT, Blaabjerg LI, et al. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine. Eur J Pharm Biopharm. 2015;96:44–52.
   PubMed Web of Science ®Google Scholar
• Jensen KT, Blaabjerg LI, Lenz E, et al. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts. J Pharm Pharmacol. 2016;68(5):615–624.
   PubMed Web of Science ®Google Scholar
• Beyer A, Radi L, Grohganz H, et al. Preparation and recrystallization behavior of spray-dried co-amorphous naproxen-indomethacin. Eur J Pharm Biopharm. 2016;104:72–81.
   PubMed Web of Science ®Google Scholar
• Ali AM, Al-Remawi MM. Freeze dried quetiapine-nicotinamide binary solid dispersions: a new strategy for improving physicochemical properties and ex vivo diffusion. J Pharm. 2016;2016:2126056.
   Google Scholar
• Ohori R, Akita T, Yamashita C. Mechanism of collapse of amorphous-based lyophilized cake induced by slow ramp during the shelf ramp process. Int J Pharm. 2019;564:461–471.
   PubMedGoogle Scholar
• Lenz E, Lobmann K, Rades T, et al. Hot melt extrusion and spray drying of co-amorphous indomethacin-arginine with polymers. J Pharm Sci. 2017;106(1):302–312.
   PubMed Web of Science ®Google Scholar
• Hitzer P, Bauerle T, Drieschner T, et al. Process analytical techniques for hot-melt extrusion and their application to amorphous solid dispersions. Anal Bioanal Chem. 2017;409(18):4321–4333.
   PubMed Web of Science ®Google Scholar
• Netchacovitch L, Thiry J, De Bleye C, et al. Vibrational spectroscopy and microspectroscopy analyzing qualitatively and quantitatively pharmaceutical hot melt extrudates. J Pharm Biomed Anal. 2015;113:21–33.
   PubMed Web of Science ®Google Scholar
• Descamps M, Willart JF. Perspectives on the amorphisation/milling relationship in pharmaceutical materials. Adv Drug Deliv Rev. 2016;100:51–66.
   PubMed Web of Science ®Google Scholar
• Krupa A, Descamps M, Willart JF, et al. High-energy ball milling as green process to vitrify tadalafil and improve bioavailability. Mol Pharm. 2016;13(11):3891–3902.
   PubMed Web of Science ®Google Scholar
• Jensen KT, Larsen FH, Cornett C, et al. Formation mechanism of coamorphous drug-amino acid mixtures. Mol Pharm. 2015;12(7):2484–2492.
   PubMedGoogle Scholar
• Willart JF, Descamps M. Solid state amorphization of pharmaceuticals. Mol Pharm. 2008;5(6):905–920.
   PubMedGoogle Scholar
• Ojarinta R, Heikkinen AT, Sievanen E, et al. Dissolution behavior of co-amorphous amino acid-indomethacin mixtures: the ability of amino acids to stabilize the supersaturated state of indomethacin. Eur J Pharm Biopharm. 2017;112:85–95.
   PubMed Web of Science ®Google Scholar
• Pang W, Lv J, Du S, et al. Preparation of curcumin-piperazine coamorphous phase and fluorescence spectroscopic and density functional theory simulation studies on the interaction with bovine serum albumin. Mol Pharm. 2017;14(9):3013–3024.
   PubMedGoogle Scholar
• Sou T, Bergstrom CAS. Automated assays for thermodynamic (equilibrium) solubility determination. Drug Discov Today Technol. 2018;27:11–19.
   PubMedGoogle Scholar
• Konczol A, Dargo G. Brief overview of solubility methods: recent trends in equilibrium solubility measurement and predictive models. Drug Discov Today Technol. 2018;27:3–10.
   PubMedGoogle Scholar
• Prachi BS, Varsha BP. Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles. Acta Pharm Sin B. 2017;7(3):260–280.
   PubMed Web of Science ®Google Scholar
• Maleki A, Kettiger H, Schoubben A, et al. Mesoporous silica materials: from physico-chemical properties to enhanced dissolution of poorly water-soluble drugs. J Control Release. 2017;262:329–347.
   PubMed Web of Science ®Google Scholar
• Priemel PA, Grohganz H, Rades T. Unintended and in situ amorphisation of pharmaceuticals. Adv Drug Deliv Rev. 2016;100:126–132.
   PubMed Web of Science ®Google Scholar
• Dahan A, Beig A, Lindley D, et al. The solubility-permeability interplay and oral drug formulation design: two heads are better than one. Adv Drug Deliv Rev. 2016;101:99–107.
   PubMed Web of Science ®Google Scholar
• Newman A, Nagapudi K, Wenslow R. Amorphous solid dispersions: A robust platform to address bioavailability challenges. Ther Deliv. 2015;6(2):247–261.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Kojima T, Karashima M, et al. Physicochemical evaluation and developability assessment of co-amorphouses of low soluble drugs and comparison to the co-crystals. Chem Pharm Bull. 2016;64(12):1739–1746.
   PubMed Web of Science ®Google Scholar
• Laitinen R, Lobmann K, Grohganz H, et al., Supersaturating drug delivery systems: the potential of co-amorphous drug formulations. Int J Pharm. 2017;532(1): 1–12.
   PubMedGoogle Scholar
• Sun DD, Wen H, Taylor LS. Non-sink dissolution conditions for predicting product quality and in vivo performance of supersaturating drug delivery systems. J Pharm Sci. 2016;105(9):2477–2488.
   PubMed Web of Science ®Google Scholar
• Taylor LS, Zhang GGZ. Physical chemistry of supersaturated solutions and implications for oral absorption. Adv Drug Deliv Rev. 2016;101:122–142.
   PubMed Web of Science ®Google Scholar
• Wei Y, Zhou S, Hao T, et al. Further enhanced dissolution and oral bioavailability of docetaxel by coamorphization with a natural P-gp inhibitor myricetin. Eur J Pharm Sci. 2019;129:21–30.
   PubMed Web of Science ®Google Scholar
• Alhalaweh A, Bergstrom CAS, Taylor LS. Compromised in vitro dissolution and membrane transport of multidrug amorphous formulations. J Control Release. 2016;229:172–182.
   PubMed Web of Science ®Google Scholar
• Trasi NS, Taylor LS. Dissolution performance of binary amorphous drug combinations–Impact of a second drug on the maximum achievable supersaturation. Int J Pharm. 2015;496(2):282–290.
   PubMedGoogle Scholar
• Trasi NS, Taylor LS. Thermodynamics of highly supersaturated aqueous solutions of poorly water-soluble drugs-impact of a second drug on the solution phase behavior and implications for combination products. J Pharm Sci. 2015;104(8):2583–2593.
   PubMed Web of Science ®Google Scholar
• Arca HC, Mosquera-Giraldo LI, Dahal D, et al. Multidrug, anti-HIV amorphous solid dispersions: nature and mechanisms of impacts of drugs on each other’s solution concentrations. Mol Pharm. 2017;14(11):3617–3627.
   PubMedGoogle Scholar
• Nuxoll E. Added release time in diffusion/dissolution coupled release. Int J Pharm. 2015;494(1):195–204.
   PubMedGoogle Scholar
• Mori K, Hori S, Kawata T, et al. The in vitro release of indomethacin from suppositories: effects of bases and comparison of different dissolution methods. Chem Pharm Bull. 2017;65(7):674–677.
   PubMed Web of Science ®Google Scholar
• Wairkar S, Gaud R. Development and characterization of microstructured, spray-dried co-amorphous mixture of antidiabetic agents stabilized by silicate. AAPS PharmSciTech. 2019;20(3):141.
   PubMed Web of Science ®Google Scholar
• Alleso M, Chieng N, Rehder S, et al., Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: amorphous naproxen-cimetidine mixtures prepared by mechanical activation. J Control Release. 2009;136(1): 45–53.
   PubMed Web of Science ®Google Scholar
• Aljohani M, MacFhionnghaile P, McArdle P, et al. Investigation of the formation of drug-drug cocrystals and coamorphous systems of the antidiabetic drug gliclazide. Int J Pharm. 2019;561:35–42.
   PubMedGoogle Scholar
• Heng W, Wei Y, Xue Y, et al. Gel formation induced slow dissolution of amorphous indomethacin. Pharm Res. 2019;36(11):159.
   PubMed Web of Science ®Google Scholar
• Pacult J, Rams-Baron M, Chmiel K, et al. How can we improve the physical stability of co-amorphous system containing flutamide and bicalutamide? The case of ternary amorphous solid dispersions. Eur J Pharm Sci. 2019;136:104947.
   PubMed Web of Science ®Google Scholar
• Phan AD, Knapik-Kowalczuk J, Paluch M, et al. Theoretical model for the structural relaxation time in coamorphous drugs. Mol Pharm. 2019;16(7):2992–2998.
   PubMedGoogle Scholar
• Riekes MK, Engelen A, Appeltans B, et al. New perspectives for fixed dose combinations of poorly water-soluble compounds: A case study with ezetimibe and lovastatin. Pharm Res. 2016;33(5):1259–1275.
   PubMed Web of Science ®Google Scholar
• Qian S, Li Z, Heng WL, et al. Charge-assisted intermolecular hydrogen bond formed in coamorphous system is important to relieve the pH-dependent solubility behavior of lurasidone hydrochloride. RSC Adv. 2016;6(108):106396–106412.
   Web of Science ®Google Scholar
• DeBoyace K, Wildfong PLD. The application of modeling and prediction to the formation and stability of amorphous solid dispersions. J Pharm Sci. 2018;107(1):57–74.
   PubMed Web of Science ®Google Scholar
• Yuan X, Sperger D, Munson EJ. Investigating miscibility and molecular mobility of nifedipine-PVP amorphous solid dispersions using solid-state NMR spectroscopy. Mol Pharm. 2014;11(1):329–337.
   PubMedGoogle Scholar
• Tian Y, Jones DS, Andrews GP. An investigation into the role of polymeric carriers on crystal growth within amorphous solid dispersion systems. Mol Pharm. 2015;12(4):1180–1192.
   PubMedGoogle Scholar
• Tian B, Tang X, Taylor LS. Investigating the correlation between miscibility and physical stability of amorphous solid dispersions using fluorescence-based techniques. Mol Pharm. 2016;13(11):3988–4000.
   PubMedGoogle Scholar
• Beyer A, Grohganz H, Lobmann K, et al. Influence of the cooling rate and the blend ratio on the physical stability of co-amorphous naproxen/indomethacin. Eur J Pharm Biopharm. 2016;109:140–148.
   PubMed Web of Science ®Google Scholar
• Grzybowska K, Capaccioli S, Paluch M. Recent developments in the experimental investigations of relaxations in pharmaceuticals by dielectric techniques at ambient and elevated pressure. Adv Drug Deliv Rev. 2016;100:158–182.
   PubMed Web of Science ®Google Scholar
• Heng W, Su M, Cheng H, et al. Incorporation of complexation into a coamorphous system dramatically enhances dissolution and eliminates gelation of amorphous lurasidone hydrochloride. Mol Pharm. 2020;17:84–97.
   PubMedGoogle Scholar
• Hirakawa Y, Ueda H, Miyano T, et al. New insight into transdermal drug delivery with supersaturated formulation based on co-amorphous system. Int J Pharm. 2019;569:118582.
   PubMedGoogle Scholar
• Liu W, Liu Y, Huang J, et al. Identification and investigation of the vibrational properties of crystalline and co-amorphous drugs with Raman and terahertz spectroscopy. Biomed Opt Express. 2019;10(8):4290–4304.
   PubMed Web of Science ®Google Scholar
• Wang C, Paul S, Wang K, et al. Relationships among crystal structures, mechanical properties, and tableting performance probed using four salts of diphenhydramine. Cryst Growth Des. 2017;17(11):6030–6040.
   Web of Science ®Google Scholar
• Petry I, Lobmann K, Grohganz H, et al. Solid state properties and drug release behavior of co-amorphous indomethacin-arginine tablets coated with kollicoat (R) protect. Eur J Pharm Biopharm. 2017;119:150–160.
   PubMed Web of Science ®Google Scholar
• Suresh K, Mannava MKC, Nangia A. A novel curcumin-artemisinin coamorphous solid: physical properties and pharmacokinetic profile. RSC Adv. 2014;4(102):58357–58361.
   Web of Science ®Google Scholar
• Khajuria A, Thusu N, Zutshi U. Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics. Phytomedicine. 2002;9(3):224–231.
   PubMed Web of Science ®Google Scholar
• Di X, Wang X, Di X, et al. Effect of piperine on the bioavailability and pharmacokinetics of emodin in rats. J Pharm Biomed Anal. 2015;115:144–149.
   PubMed Web of Science ®Google Scholar